You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

Claims for Patent: 8,007,796


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 8,007,796
Title:Means and methods for the treatment of tumorous diseases
Abstract: The invention relates to pharmaceutical means and methods for the prevention, treatment or amelioration of indolent or aggressive B cell non-Hodgkin lymphoma (B NHL) and B cell leukemia comprising the administration of a bispecific single chain antibody construct to a subject and the use of the bispecific single chain antibody construct for the preparation of a pharmaceutical composition for the prevention, treatment or amelioration of indolent or aggressive B cell non-Hodgkin lymphoma (B NHL) and B cell leukemia. The construct is to be administered for at least 1 week in specified daily doses. Moreover, the invention relates to kits comprising a bispecific single chain antibody construct to be used in accordance with this invention.
Inventor(s): Baeuerle; Patrick (Gauting, DE), Kufer; Peter (Moosburg, DE), Klinger; Matthias (Gilching, DE), Leo; Eugen (Koln, DE)
Assignee: Micromet AG (Munich, DE)
Application Number:12/095,951
Patent Claims:1. A method for the treatment or amelioration of indolent or aggressive B cell non-Hodgkin lymphoma (B NHL) or B cell leukemia, the method comprising the administration of a pharmaceutical composition comprising a bispecific single chain antibody construct to a subject in the need thereof, said bispecific single chain antibody construct comprising binding domains specific for human CD3 and human CD19, wherein the corresponding variable heavy chain regions (V.sub.H) and the corresponding variable light chain regions (V.sub.L) regions are arranged, from N-terminus to C-terminus, in the order, V.sub.L(CD19)-V.sub.H(CD19)-V.sub.H(CD3)-V.sub.L(CD3), V.sub.H(CD19)-V.sub.L(CD19)-V.sub.H(CD3)-V.sub.L(CD3), V.sub.H(CD3)-V.sub.L(CD3)-V.sub.H(CD19)-V.sub.L(CD19) or V.sub.H(CD3)-V.sub.L(CD3)-V.sub.L(CD19)-V.sub.H(CD19), wherein the bispecific single chain antibody construct is administered for at least 1 week in a daily dose of 10 .mu.g to 80 .mu.g per square meter patient body surface area and wherein the daily dose is administered over at least 6 h, and wherein each VL and VH region comprises a CDR1, CDR2, and CDR3 region.

2. The method according to claim 1, wherein the daily dose is administered over at least 10 h.

3. The method according to claim 1, wherein the daily dose is administered over at least 12 h.

4. The method according to claim 1, wherein the daily doses is administered over 24 h.

5. The method according to claim 1, wherein said V.sub.H and V.sub.L regions of said CD3 specific domain are from a CD3 specific antibody selected from the group consisting of: OKT-3, X35-3, VIT3, BMA030 (BW264/56), CLB-T3/3, CRIS7, YTH12.5, F111-409, TR-66, WT31, WT32, SPv-T3b, 11D8, XIII-141, XIII-46, XIII-87, 12F6, T3/RW2-8C8, T3/RW2-4B6, OKT3D, M-T301, SMC2 and F101.01.

6. The method according to claim 1, wherein said V.sub.H region of said CD3 specific domain comprises at least one CDR3 region comprising the amino acid sequence: SEQ ID NO. 11.

7. The method according to claim 1, wherein said V.sub.H region of said CD3 specific domain comprises at least one CDR2 region comprising the amino acid sequence: SEQ ID NO. 10.

8. The method according to claim 1, wherein said V.sub.H region of said CD3 specific domain comprises at least one CDR1 region comprising the amino acid sequence: SEQ ID NO. 9.

9. The method according to claim 1, wherein said V.sub.L region of said CD3 specific domain comprises at least one CDR3 region comprising the amino acid sequence: SEQ ID NO. 14.

10. The method according to claim 1, wherein said V.sub.L region of said CD3 specific domain comprises at least one CDR2 region comprising the amino acid sequence: SEQ ID NO. 13.

11. The method according to claim 1, wherein said V.sub.L region of said CD3 specific domain comprises at least one CDR1 region comprising the amino acid sequence: SEQ ID NO. 12.

12. The method according to claim 1, wherein said VH region of said CD3 specific domain comprises SEQ ID NO. 17, said VH region of said CD19 specific domain comprises SEQ ID NO. 15, said VL region of said CD3 specific domain comprises SEQ ID NO. 18 and/or said VL region of said CD19 specific domain comprises SEQ ID NO. 16.

13. The method according to claim 1, wherein said bispecific single chain antibody construct comprises an amino acid sequence selected from the group consisting of (a) an amino acid sequence as depicted in SEQ ID NOs 2, 4, 6, or 8; (b) an amino acid sequence encoded by a nucleic acid sequence as shown in SEQ ID NOs 1, 3, 5, or 7; and (c) an amino acid sequence encoded by a nucleic acid sequence which is degenerate as a result of the genetic code to a nucleotide sequence of (b), wherein said amino acid sequence is capable of specifically binding to CD3 and CD19.

14. The method according to claim 1, wherein said variable domains are connected by additional linker sequences.

15. The method according to claim 1, wherein the daily administration is continued for at least 2 weeks, at least 3 weeks or at least 4 weeks.

16. The method according to claim 1, wherein the pharmaceutical composition is administered in combination with one or more further pharmaceutical agents.

17. The method according to claim 1, wherein the pharmaceutical composition is administered to a human patient.

18. The method according to claim 1, wherein the bispecific single chain antibody construct is administered in a daily dose of less than 10 .mu.g to 80 .mu.g per square meter patient body surface area on the first day.

International Patent Family for US Patent 8,007,796

Country Patent Number Estimated Expiration
South Africa 200806095 ⤷  Try a Trial
World Intellectual Property Organization (WIPO) 2007068354 ⤷  Try a Trial
United States of America 2022088196 ⤷  Try a Trial
United States of America 2013095103 ⤷  Try a Trial
United States of America 2009291072 ⤷  Try a Trial
United States of America 11154617 ⤷  Try a Trial
>Country >Patent Number >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.